Abstract: A multidimensional security situation real-time presentation method according to an embodiment includes selecting security testing cases of at least one dimensionality based on a test instruction to generate a target test set, and generating a corresponding target log set according to the target test set, determining a difference log set according to the target log set and a monitoring log set, and performing real-time output display of difference log events, test processing time periods, enhanced training nodes and a test processing efficiency corresponding to the difference log set.

Abstract: A multidimensional security situation real-time presentation method according to an embodiment includes selecting security testing cases of at least one dimensionality based on a test instruction to generate a target test set, and generating a corresponding target log set according to the target test set, determining a difference log set according to the target log set and a monitoring log set, and performing real-time output display of difference log events, test processing time periods, enhanced training nodes and a test processing efficiency corresponding to the difference log set.

Abstract: The present invention is directed to methods of treating cells infected with HCV and mammals suffering from HCV infection by transfecting the infected cells with miRNA-196 mimic. miRNA-196 mimic significantly down-regulates Bach1 protein and HCV gene expression, while also up-regulating HMOX1 gene expression. miRNA-196 binds with the 3?-UTR of Bach1 mRNA to reduce the expression of Bach1. As such, miRNA-196 can play an important role in the regulation of HCV replication and HMOX1/Bach1 expression in hepatocytes. The present invention also provides a formulation for the treatment of cells expressing HCV comprising a therapeutically effective amount of miRNA-196 such that Bach1 and HCV gene expression are down-regulated while HMOX1 expression is increased. The formulations are adapted to enable the transfection of miRNA-196 mimic into hepatocytes expressing HCV proteins.

Abstract: The present invention is directed to the treatment of hepatitis C infection with a metalloporphyrin. In particular, the present invention is based on the discovery that the NS5A protein plays a key role in HCV RNA replication by participating in polyprotein cleavage, interferon response and cellular signaling pathways. It has been found that metalloporphyrins, such as zinc porphyrins, induce post-translational down-regulation of HCV NS5A protein in an ubquitin-proteasome degradation pathway. That is, metalloporphyrins can be used to activate the ubiquitin-proteasomal pathway of NS5A protein catabolism. As a result, metalloporphyrins can be used to significantly suppress HCV viral replication in HCV infected cells.